Pfizer launches human trials for coronavirus vaccine, aims for emergency use in September


Pfizer, in partnership with German pharmaceutical company BioNTech, became the latest company to launch human trials for a potential coronavirus vaccine Monday.
If all goes well, the companies hope their COVID-19 vaccine could be ready for emergency use in September, in time for what many predict will be a period of rejuvenated viral transmission (if it subsides at all in the U.S. between now and then). The normal caveats apply here — the quest for a vaccine is moving along at a pace never before seen, which means that some essential steps may be purposefully skipped in the process, and many experts believe that getting a vaccine in even 18 months, let alone later this year, is overly optimistic.
Pfizer and some other companies are using a genetic material known as messenger RNA to develop their vaccine that could possibly train cells to create a protein the coronavirus latches onto without making a person sick. With the protein in the body, a person's immune system could then reportedly produce antibodies ready to fight off a future infection. The good news is that this technology is reportedly more stable than traditional vaccines which use weakened virus strains, and it's faster to produce, hence Pfizer's ambitious timeline. The catch is that no RNA messenger vaccine has ever reached the market before.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
In other coronavirus development news, the United Arab Emirates found that a "minimally invasive" treatment in which stem cells are turned into a mist to be inhaled has resulted in "favorable" outcomes for COVID-19 patients and could hit the market in three months if trials keep going well. Israel, meanwhile, said it has isolated a key coronavirus antibody that could possibly "neutralize" the virus in a patient's body.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Critics' choice: Steak houses that break from tradition
Feature Eight hours of slow-roasting prime rib, a 41-ounce steak, and a former Catholic school chapel turned steakhouse
-
Tash Aw's 6 favorite books about forbidden love
Feature The Malaysian novelist recommends works by James Baldwin, Toni Morrison, and more
-
France and Indonesia promote a contentious bid for an Israel-Palestine two-state solution
Talking Points Both countries have said a two-state solution is the way to end the Middle East conflict
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study finds
Speed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influence
Speed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
RFK Jr. offers alternative remedies as measles spreads
Speed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows